Fast acting inhibitor of gastric acid secretion
The present invention relates to the use of pharmaceutically acceptable zinc salts, in particular, zinc chloride and zinc acetate alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2-blocker, cytoprotective agent or a combination of agents as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, including acid secretion in the fundus (by inhibiting vacuolar H + -ATPase or H + /K + -ATPase) and upper body region of the stomach (by inhibiting H + /K + -ATPase), thus raising the pH of gastric juices in rapid fashion and decreasing the duration of stomach acid release during a secretagogue phase. The method is also directed to treating conditions including gastroesophogeal reflux disease, non-erosive reflux disease, Zollinger-Ellison syndrome, ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to PPIs and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion.
1. A method of increasing the pH of the gastric juices of the stomach of a human patient in need of a rapid increase in stomach pH, said method comprising orally administering to said patient an effective amount of a composition consisting essentially of at least one zinc salt selected from the group consisting of zinc chloride, zinc acetate, and mixtures thereof, wherein said pH of said gastric juices in said patient increases to at least about 3.0 within a period no greater than about one hour after administration in response to said zinc salt(s).
2. A method of reducing the likelihood of an ulcer developing in a human patient at risk for an ulcer because of elevated acid release in the stomach of said patient by rapidly increasing pH of the gastric juices of the stomach in said patient in response to said acid release comprising orally administering to said patient at risk an effective amount of a composition consisting essentially of at least one pharmaceutically acceptable zinc salt selected from the group consisting of zinc acetate, zinc chloride, and mixtures thereof, wherein the administration of said zinc salt(s) increases the pH of gastric juices in the stomach of said patient to at least about 3.0 within a period no greater than about one hour after administration in response to said zinc salt(s).
3. A method of treating a human patient in need for a disease state or condition in which elevated release of acid in the stomach of said patient occurs selected from the group consisting of gastroesophageal reflux disease, (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE syndrome), ulcer disease and gastric cancer comprising orally administering to said patient an effective amount of a composition to rapidly increase pH of the gastric juices of the stomach in said patient in response to said release of acid consisting essentially of at least one pharmaceutically acceptable zinc salt selected from the group consisting of zinc acetate, zinc chloride, and mixtures thereof, wherein the administration of said zinc salt(s) increases the pH of gastric juices in the stomach of said patient to at least about 3.0 within a period no greater than about one hour after administration in response to said zinc salt(s).
4. The method according to claim 3 wherein said zinc salt or mixture of zinc salts is coadministered with at least one agent selected from the group consisting of a proton pump inhibitor, an H2 blocker, a cytoprotective agent or a mixture of two or more of these agents.
5. The method according to claim 3 wherein said disease state or condition is GERD, NERD or ZE syndrome.
6. A method of inhibiting vacuolar H + -ATPase, H + , K + -ATPase or both H + -ATPase and H + , K˜-ATPase in the stomach of a human patient in need in which elevated release of acid in the stomach of said patient occurs comprising administering to said patient an effective amount of a composition to rapidly increase pH of the gastric juices of the stomach in said patient in response to said release of acid consisting essentially of at least one pharmaceutically acceptable zinc salt selected from the group consisting of zinc acetate, zinc chloride, and mixtures thereof, wherein the administration of said zinc salt(s) increases the pH of gastric juices in the stomach of said patient to at least about 3.0 within a period no greater than about one hour after administration in response to said zinc salt(s).
7. The method according to claim 1 wherein said zinc salt is zinc acetate, or zinc chloride.
8. The method according to claim 1 wherein a mixture of at least two zinc salts is administered to said patient.
9. The method according to claim 8 wherein said mixture of zinc salts is a mixture of zinc acetate and zinc chloride.
10. The method according to claim 1 wherein said zinc salt is zinc chloride and optionally, at least one additional zinc salt selected from the group consisting of zinc acetate.
11. The method according to claim 1 wherein said zinc salt is zinc chloride.
12. The method according to claim 7 wherein said pH of said gastric juices in said patient increases to at least about 3.5 within a period no greater than about 30 minutes after administration of said zinc salt(s).
13. The method according to claim 7 wherein said pH of said gastric juices in said patient increases to at least 4.0 within a period no greater than about 20 minutes after administration of said zinc salt(s).
14. The method according to claim 7 wherein said zinc salt(s) is coadministered with at least one proton pump inhibitor.
15. The method according to claim 14 wherein said proton pump inhibitor is selected from the group consisting of omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole.
16. The method according to claim 2 wherein a mixture of at least two zinc salts is administered to said patient.
17. The method according to claim 16 wherein said mixture of zinc salts is a mixture of zinc acetate and zinc chloride.
18. The method according to claim 2 wherein said zinc salt is combined with an effective amount of at least one proton pump inhibitor.
19. The method according to claim 18 wherein said proton pump inhibitor is selected from the group consisting of omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole and mixtures thereof.
20. The method according to claim 3 wherein a mixture of at least two zinc salts is administered to said patient.
21. The method according to claim 20 wherein said mixture of zinc salts is a mixture of zinc acetate and zinc chloride.
22. The method according to claim 3 wherein said zinc salt is zinc chloride and optionally, at least one additional zinc salt selected from the group consisting of zinc acetate and.
23. The method according to claim 3 wherein said zinc salt is zinc chloride.
24. The method according to claim 3 wherein said pH of said gastric juices in said patient increases to at least about 3.5 within a period no greater than about 30 minutes after administration of said zinc salt(s).
25. The method according to claim 3 wherein said pH of said gastric juices in said patient increases to at least 4.0 within a period no greater than about 20 minutes after administration of said zinc salt(s).
26. The method according to claim 4 wherein said proton pump inhibitor is selected from the group consisting of omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole.
27. The method according to claim 4 wherein said H2 blocker is cimetidine, famotidine, nizatidine, ranitidine or mixtures thereof.
28. The method according to claim 4 wherein said cytoprotective agent is bismuth subsalicylate, sucralfate or mixtures thereof.
29. The method according to claim 4 wherein said mixture of agents is prevpac.
30. The method according to claim 6 wherein a mixture of at least two zinc salts is administered to said patient.
31. The method according to claim 6 wherein said zinc salt is selected from the group consisting of zinc acetate and zinc chloride.
32. The method according to claim 6 wherein said zinc salt is zinc chloride and optionally, at least one additional zinc salt selected from the group consisting of zinc acetate.
33. The method according to claim 6 wherein said zinc salt is zinc chloride.
34. The method according to claim 6 wherein said pH of said gastric juices in said patient increases to at least about 3.5 within a period no greater than about 30 minutes after administration of said zinc salt(s).
35. The method according to claim 6 wherein said pH of said gastric juices in said patient increases to at least 4.0 within a period no greater than about 20 minutes after administration of said zinc salt(s).
36. The method according to claim 6 wherein said zinc salt or mixture of zinc salts is coadministered with at least one proton pump inhibitor.
37. The method according to claim 36 wherein said proton pump inhibitor is selected from the group consisting of omeprazole, esomeprazole, lansoprazole, pantoprazole and rabeprazole.
38. The method according to claim 6 wherein said patient does not effectively respond to proton pump inhibitor therapy.
39. The method according to claim 38 wherein the administration of said zinc salt(s) increases the pH of gastric juices in the stomach of said patient to at least about 3.5 within a period no greater than about 30 minutes after administration of said zinc salt(s).